One of the many financial newsletters that are out there had as its headline today, "So Many Worries, So Little Time," suggesting that there was so much bad news out there that most investors would think that the only rational course of action in this market is to sell everything and be all in cash.  (Not gold; gold is doing worse than even real estate the last several years.)  But today's news is yet another demonstration that this view of the market could not be further from the truth.  The market ended just about even after first losing about 50 points, then gaining, then losing again to end down just 2.5 points.  Why all the back and forth?  Because there is so much good news out there that the old interest rate hike fire has been stoked again.  Not only were financials up but job openings surged to a record high along with an increase in small business confidence.  When even the skeptics who run the nation's small businesses see hope on the horizon, that's gotta be good.  So today's expert from Prudential Financial states, "It's a market that's searching for a rationale at this point ... and waiting for next week's (Fed) meeting."  There is no rationale to search for.  The fact is investors are suffering from irrational panic in the midst of an onslaught of good news so the only thing the market should be searching for is some good old-fashioned common sense.  And if anyone thinks that next week's Fed meeting is going to make any difference at all, they haven't been paying attention for the last few years.  But as I have already pointed out a number of times, none of this much matters.  Volume was just below recent light averages at 5.9 billion, which means the same players are making all the trades and, until that changes I say, "No worries, and we've got all kinds of time!"

Markets | Tue Jun 9, 2015 6:31pm EDT

Wall Street ends flat; S&P 500 snaps three-day losing streak

NEW YORK | BY CAROLINE VALETKEVITCH

DJ:   17,764.04  -2.51          NAS:   5,013.87  -7.76         S&P:      2,080.15  +0.87

(Reuters) U.S. stocks ended flat on Tuesday though the S&P 500 snapped three days of losses as financial and consumer staples shares bounced.

Shares of biotech companies were among the biggest drags, including Biogen (BIIB.O), down 1.1 percent at $382. The Nasdaq Biotech Index .NBI was down 0.7 percent.

The S&P financials .SPSY were up 0.3 percent, helped by prospects for higher interest rates, while S&P consumer staples .SPLRCS rose 0.5 percent, led by a 1.5 percent gain in Procter & Gamble (PG.N)

"People are sick of timing the Fed when it comes to this sector. People don't want to miss the boat," said Andrew Frankel, co-president of Stuart Frankel & Co in New York regarding the rise in financial shares.

Another batch of strong economic data underscored views that the Federal Reserve could raise interest rates in September.

Data showed that U.S. job openings surged to a record high in April and small business confidence increased in May, signs that the economy was regaining momentum after stumbling at the start of the year.

The Dow Jones industrial average .DJI fell 2.51 points, or 0.01 percent, to 17,764.04, the S&P 500 .SPX gained 0.87 points, or 0.04 percent, to 2,080.15 and the Nasdaq Composite .IXIC dropped 7.76 points, or 0.15 percent, to 5,013.87.

The Dow Jones transportation average .DJT ended down 0.3 percent, just shy of correction territory, which would be a drop of 10 percent from its Dec. 29, 2014, record close of 9,217.44.

"It's a market that's searching for a rationale at this point ... and waiting for next week's (Fed) meeting," said Quincy Krosby, market strategist at Prudential Financial, which is based in Newark, New Jersey.

Shares of Procter & Gamble climbed 1.5 percent to $78.90, leading gains in the staples sector, after Reuters, citing people familiar with the matter, reported late Monday that Henkel & Co (HNKG_p.DE) and Coty Inc (COTY.N) made binding offers to buy separate parts of Procter & Gamble Co's beauty businesses.

Shares of Hovnanian Enterprises (HOV.N) dropped 9.8 percent to $2.86, the lowest since 2012, after disappointing results.

Lululemon (LULU.O) shares rose 11 percent to $68.27 after the Canadian yogawear retailer raised its full-year revenue and earnings forecast.

Sage Therapeutics (SAGE.O) jumped 15.4 percent to $86.71 after its experimental injectable drug was found to be effective in treating postpartum depression.

Declining issues outnumbered advancing ones on the NYSE by 1,976 to 1,066, for a 1.85-to-1 ratio on the downside; on the Nasdaq, 1,645 issues fell and 1,093 advanced for a 1.51-to-1 ratio favoring decliners.

The S&P 500 posted 10 new 52-week highs and nine new lows; the Nasdaq Composite recorded 88 new highs and 46 new lows.

About 5.9 billion shares changed hands on U.S. exchanges, about even with the 6.1 billion daily average for the month to date, according to data from BATS Global Markets.